A new report from GTHT highlights that the burden of Alzheimer's disease (AD) is immense and continuing to expand. Traditional symptomatic treatments have entered a plateau phase, while anti-Aβ monoclonal antibodies are ushering in a new era of disease-modifying therapy (DMT). The report notes that multi-mechanism small molecules and next-generation brain-penetration technologies are poised to further overcome the delivery challenges of the blood-brain barrier, with domestic innovative drug companies demonstrating strong competitiveness in their pipeline layouts.
Massive Disease Burden, DMT Opens Market Expansion
The number of Alzheimer's disease patients in China is projected to grow from 12.5 million in 2020 to 15.1 million in 2025, and is expected to reach 18.0 million and 21.5 million by 2030 and 2035, respectively, with growth rates consistently outpacing global averages. The Chinese neurodegenerative disease drug market is estimated at approximately $2.6 billion in 2025, with projections to increase to $5.5 billion by 2030 (a CAGR of about 16.0%), significantly faster than the global growth rate of 8.1%.
Traditional Symptom Drugs Slowing, Aβ Monoclonal Antibody DMTs Accelerating Penetration
Traditional drugs like donepezil only alleviate symptoms and have entered a plateau phase of existing market share. Since 2023, anti-Aβ monoclonal antibodies such as lecanemab and donanemab have been approved, marking a breakthrough in clearing Aβ from its source. The AD treatment market is rapidly shifting from symptomatic treatment to disease-modifying therapy.
Limitations of Aβ Monoclonal Antibodies, Multi-Mechanism Oral Small Molecules as a Key Supplement
Intravenous administration suffers from poor patient compliance, risks of ARIA, and high costs, which limit its widespread adoption. In contrast, the oral Aβ aggregation inhibitor ALZ-801 has shown significant efficacy and brain-protective effects in early-stage MCI subgroups, highlighting the advantages of convenient oral dosing.
Next-Generation Brain-Penetration Technology Enhances Delivery and Reduces Safety Risks
Receptor-mediated transport platforms (such as TfR/ATV) and focused ultrasound technology are overcoming the blood-brain barrier bottleneck. Animal models show brain drug concentrations increased by 5-8 times, with ARIA-like lesions nearly eliminated.
Local Companies Demonstrate Competitive Pipeline Strength
Key players include Kangnuoyi with CM383 (boasting a superior half-life compared to approved anti-Aβ antibodies), Harbour BioMed with NEU2005 (a bispecific antibody) and NEU3001 (an AOC), Akeso with AK152 (China's first Aβ/BBB bispecific antibody, now in Phase I), and Shandong Xinhua Pharmaceutical with OAB-14 (a novel oral RXR agonist with a new mechanism of action, with Phase 2a enrollment completed).
Risk Factors
Risks include the failure of innovative drug development, clinical trial progress falling short of expectations, drug sales not meeting forecasts, and challenges in out-licensing domestic drugs overseas.